Fecal excretion of FDG by metformin in FDG-PET

Fecal excretion of FDG by metformin in FDG-PET - Fecal excretion of FDG by metformin in FDG-PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000040785

Enrollment

Registered

2020-06-16

Start date

2020-01-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Inducing Defecation with laxative

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Adult. Regardless of gender 2) Those who have 18F-FDG accumulated visually in the intestinal tract after the descending colon by FDG-PET/CT test.

Exclusion criteria

Exclusion criteria: 1) Gastrointestinal cancer 2) Stubborn constipation 3) Inflammatory bowel disease 4) Patients with intestinal bleeding, inflammation in the abdominal cavity or perforation or risk of perforation of the intestinal tract. 5) Nausea, vomiting or severe abdominal pain 6) Patients just after lower gastrointestinal surgery 7) Patients with ischemic heart disease 8) People with general weakness

Design outcomes

Primary

Measure	Time frame
Fecal FDG excretion of metformin in FDG-PET	—

Countries

Japan

Contacts

Public ContactShuko Minami

Public interest incorporated association,Kagoshima Kyousaikai,Nanpuh Hospital Clinical Research Support Office

crc-kenkyu@nanpuh.or.jp0998052663

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026